The Obesity Treatments (Oral) theme has 8 member stock(s) today, with an average return of -0.3%. The leading stock is 킵스파마 (+6.9%, trading value 1,263,996,170).
A theme focused on developing obesity treatments in pill form, which overcomes the limitations of existing injectable formats (GLP-1 class) and dramatically improves convenience of administration. Stock prices react sensitively to clinical data from major global pharmaceutical companies and domestic pharma-tech firms.
| Stock | Price | Return | Trading Value |
|---|---|---|---|
| 킵스파마 | 6,030 | +6.9% | 1,263,996,170 |
| 한미약품 | 474,000 | +2.2% | 62,382,170,750 |
| 대웅제약 | 111,100 | -0.7% | 1,374,070,900 |
| 케어젠 | 41,000 | -1.7% | 2,802,008,150 |
| 삼천당제약 | 157,800 | -1.8% | 9,013,294,600 |
| 에이비엘바이오 | 64,900 | -1.8% | 9,800,382,300 |
| 일동제약 | 14,990 | -2.1% | 2,946,839,070 |
| 디앤디파마텍 | 46,050 | -3.1% | 20,447,397,925 |
This page's data is for reference only and is not investment advice. Actual market data may differ.